Genocea Biosciences Inc. buy tamam
Summary
This prediction ended on 04.03.19 with a price of €5.49. The BUY prediction by tamam for Genocea Biosciences Inc. performed very badly with a performance of -31.14%. tamam has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Genocea Biosciences Inc. | - | - | - | - |
iShares Core DAX® | -2.023% | -3.140% | 10.499% | 13.078% |
iShares Nasdaq 100 | 4.625% | 8.753% | 34.939% | 57.906% |
iShares Nikkei 225® | -2.088% | -0.980% | 3.292% | 2.524% |
iShares S&P 500 | 2.398% | 4.677% | 27.998% | 49.604% |
Comments by tamam for this prediction
In the thread Genocea Biosciences Inc. diskutieren
tamam stimmt der Buy-Einschätzung von stratec zu
tamam stimmt am 07.03.2018 der Buy-Einschätzung von stratec mit dem Kursziel 3$ zu.
Überschrift: Genocea : Cantor sees five-bagger potential